Associate Director, Early Stage Process Development at Adverum Biotechnologies, Inc.
George Todorov specializes in HEK293-based rAAV manufacturing methods. He has a background in cell and molecular biology, with 6 years of experience in rAAV biology and process development. George currently leads the Early Stage Process Development team at Adverum Biotechnologies, with the responsibility of supporting Adverum’s candidate discovery pipeline in addition to scale-up and refinement of rAAV manufacturing platforms.
Prior to his venture into Gene Therapy, George explored research aimed at treating Polycystic Kidney Disease, Leukemia, and various solid cancers. His contributions to the Polycystic Kidney Disease and the Gene Therapy fields have been published in PNAS (2011) and presented at the ASGCT (2015) and ESGCT (2019) conferences. George holds a BS degree in Biological Sciences from the University of California Santa Barbara, and a MS degree in Biotechnology from the University of California Irvine.